Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myeloid cell surface antigen (CD33)
- Target
- CD33
- Molecular classification
- Receptor, Immunoglobulin superfamily, Transmembrane protein, Sialic acid-binding immunoglobulin-like lectin (Siglec)
01
Overview
CD33 is a transmembrane receptor primarily expressed on myeloid cells, including monocytes, myeloid progenitors, and granulocyte/macrophage precursors. It functions as an inhibitory receptor, regulating immune and myeloid cell activity through its ITIM domains, which recruit phosphatases upon ligand binding. It is a key diagnostic marker and therapeutic target for Acute Myeloid Leukemia (AML).
- Other names
- Siglec-3SIGLEC3gp67p67
02
Mechanism of action
Antibody-mediated cytotoxicity and delivery of cytotoxic agent (calicheamicin) to CD33-expressing cells
03
Biological functions
Immune regulationInhibition of cellular activationInhibition of phagocytosisHematopoietic cell lineage specificationRegulation of immune cell resting state
04
Disease associations
Acute Myeloid Leukemia (AML)Cancer
05
Safety considerations
Hematopoietic toxicityNeutropeniaThrombocytopeniaCytopenias
06
Interacting drugs
Gemtuzumab Ozogamicin
07
Biomarkers
CD33 expression level on AML blasts (diagnostic and predictive)
Beyond the preview
Go deeper on Myeloid cell surface antigen (CD33).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myeloid cell surface antigen (CD33).